Women's Health

The approval extends the use of Liletta for an additional 2 years.

An over-the-counter (OTC) progestin only pill (POP) could potentially reduce the overall number of unintended pregnancies in the United States.

Patients can face risks like hypertension and difficult delivery.

More and more women are being diagnosed with ADHD in adulthood. What's behind this increase?

What does the uptake look like for one of the most common vaccines given during pregnancy—and what does this mean for the future?

Improving vaccination rates for the most common STI in the United States could be as simple as increasing knowledge about HPV.

Hormonal implants are generally thought to be safe for bone, although whether a young adolescent would reach their genetically determined PBM while using a contraceptive implant is not known.

History of migraine may be associated with poor sleep in premenopausal and perimenopausal women, according to research presented at the North American Menopause Society Annual Meeting.

New data indicate that a diabetes diagnosis may be associated with earlier onset of menopause.

The move is meant to expand access to reproductive health care for women in the state.

In a recent study, participants who had received a COVID-19 vaccine saw an average increase in menstrual cycle length of less than 1 day.

In a recent study, it was found that access to contraceptive services declined during the COVID-19 pandemic.

The compound may also provide a synergistic effect in combination with fluconazole.

Infants of fully vaccinated mothers had fewer cases of hospitalization from COVID-19 than those unvaccinated.

CBD can be used to treat a myriad of women’s health conditions, but research is still limited.

More women are using medical cannabis for menopause-related symptoms.

New research should give expectant mothers some peace of mind.

Myovant Sciences and Pfizer announces the FDA has approved the therapy for the once-daily treatment of moderate-to-severe endometriosis-associated pain.

This is the first approved therapy targeted to patients with the HER2-low breast cancer subtype. Its approval comes four months ahead of its PDUFA action date.

Oteseconazole treats recurrent vulvovaginal candidiasis in women without reproductive potential.

There are numerous methods of contraception available for adolescents.

Perimenopausal, menopausal, and postmenopausal women experienced a progressive improvement in hair growth, shedding, quality of life, and menopausal symptoms after 12 months with an active nutraceutical supplement.

Perrigo’s HRA Pharma has submitted an application to the FDA for possible future approval of the first-ever OTC birth control pill.

Results suggest the potential of this oral therapy to address the unmet clinical need for long-term medical treatment for endometriosis.

The Department of Health and Human Services (HHS) launched a website Friday which offers women a comprehensive list of reproductive health care resources, services, and information.